Contraception
Volume 78, Issue 5 , Pages 377-383 , November 2008

Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives

  • Jeanne Loughlin

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 781 472 8460; fax: +1 781 472 8464.
    • ,
  • John D. Seeger

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    • ,
  • P. Mona Eng

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Marie Foegh

      Affiliations

    • Division of Nephrology, Department of Medicine, Georgetown University Medical School, Washington, DC 20057, USA
    • Agile Therapeutics, Inc., Princeton, NJ 08540, USA
    • ,
  • C. Robin Clifford

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Jennifer Cutone

      Affiliations

    • Veristat, Inc., Holliston, MA 01746, USA
    • ,
  • Alexander M. Walker

      Affiliations

    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    • World Health Information Science Consultants, LLC, Wellesley, MA 02481, USA

Received 10 April 2008 ,Revised 26 June 2008 ,Accepted 27 June 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was funded by a research contract between Ingenix i3 Drug Safety and Berlex (now a unit of Bayer Health Care). The contract granted i3 Drug Safety oversight of the study conduct, reporting and interpretation, as well as final wording of any resulting manuscripts.

PII: S0010-7824(08)00342-9

doi: 10.1016/j.contraception.2008.06.012

Contraception
Volume 78, Issue 5 , Pages 377-383 , November 2008

Article Tools

* Image Usage & Resolution